EMEA-000715-PIP02-11-M03

Key facts

Invented name
Otezla
Active substance
apremilast
Therapeutic area
Immunology-Rheumatology-Transplantation
Decision number
P/0080/2019
PIP number
EMEA-000715-PIP02-11-M03
Pharmaceutical form(s)
  • Tablets
  • Oral liquid
Condition(s) / indication(s)
Treatment of chronic idiopathic arthritis (including rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and juvenile idiopathic arthritis)
Route(s) of administration
Oral use
Contact for public enquiries
Celgene Europe B.V.

Tel. +41 327298500
E-mail: medinfo.intl@celgene.com

Decision type
PM: decision on the application for modification of an agreed PIP

Decision

How useful was this page?

Add your rating